corona
viru
diseas
spread
rapidli
countri
region
oversea
case
infect
result
three
thousand
death
rapid
diagnosi
patient
remain
bottleneck
contain
progress
epidem
use
autom
chemiluminesc
immunoassay
detect
serum
igm
igg
antibodi
subject
patient
becom
reactiv
posit
specif
antibodi
day
onset
morbid
specif
igm
igg
increas
progress
diseas
area
roc
curv
igm
igg
respect
specif
antibodi
detect
good
sensit
specif
detect
specif
antibodi
patient
fever
good
distinct
diseas
complement
nucleic
acid
diagnosi
earli
diagnosi
suspect
case
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
coronavirus
cov
envelop
singlestrand
positivesens
rna
virus
wide
distribut
human
mammal
coronavirus
usual
caus
respiratori
digest
nervou
system
diseas
human
anim
past
year
coronaviru
caus
two
global
epidem
sever
respiratori
infecti
diseas
one
sever
acut
respiratori
syndrom
sar
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
swab
howev
actual
diagnosi
treatment
sensit
nucleic
acid
detect
ideal
enough
confirm
case
posit
result
moreov
confirm
case
nucleic
acid
test
often
took
four
test
get
posit
result
necessari
use
fast
conveni
method
realiz
rapid
diagnosi
infect
viru
infect
organ
immun
system
carri
immun
defens
viru
produc
specif
antibodi
laboratori
diagnosi
infecti
diseas
detect
specif
antibodi
pathogen
sensit
method
fast
diagnosi
howev
antibodi
produc
chang
progress
still
unclear
studi
use
autom
chemiluminesc
immunoassay
detect
serum
igm
igg
antibodi
understand
process
antibodi
product
diseas
progress
evalu
valu
antibodi
detect
laboratori
diagnosi
studi
conduct
accord
intern
coordin
council
clinic
trial
helsinki
declar
approv
hospit
ethic
review
committe
ethic
patient
inform
consent
exempt
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
anoth
outpati
diseas
period
medic
staff
work
fever
clinic
healthi
physic
examine
collect
name
diseas
group
medic
staff
group
health
control
group
respect
accord
unifi
form
two
resid
collect
clinic
data
medic
record
separ
blood
sampl
fast
venou
blood
collect
subject
put
yellow
head
vacuum
tube
contain
separ
gel
centrifug
serum
sampl
store
ct
valu
nucleic
acid
test
result
interpret
accord
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
recommend
manufactur
instruct
suspici
result
notifi
clinic
resampl
reexamin
order
diagnos
posit
laboratori
test
result
necessari
meet
standard
n
gene
sampl
show
least
one
target
specif
rtpcr
test
result
posit
diagnosi
made
accord
diagnosi
treatment
plan
quantit
variabl
express
median
normal
variabl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
test
use
kolmogorovsmirnov
test
ldsttest
comparison
among
group
receiv
oper
characterist
curv
roc
plot
evalu
diagnost
perform
correl
determin
spearman
rank
correl
z
test
use
compar
auc
two
group
test
two
side
p
valu
consid
statist
signific
case
confirm
case
male
femal
age
rang
year
patient
diabet
hypertens
respect
common
case
sever
case
case
histori
wuhan
contact
case
clear
epidemiolog
histori
tabl
main
laboratori
find
patient
normal
slightli
low
white
blood
cell
lymphocyt
elev
inflammatori
indic
procalcitonin
creactiv
protein
serum
amyloid
erythrocyt
sediment
rate
normal
myocardi
marker
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
show
level
igg
continu
higher
igm
two
case
show
level
igm
increas
igg
week
morbid
tabl
diseas
medic
staff
health
control
group
case
reactiv
igm
igg
case
singl
reactiv
igm
igg
sensit
igm
igg
specif
igm
igg
tabl
case
case
detect
influenza
rna
case
detect
influenza
b
rna
respect
case
detect
adenoviru
dna
case
detect
mycoplasma
pneumonia
dna
tabl
also
compar
antibodi
valu
distribut
differ
group
igm
level
higher
healthi
control
group
differ
statist
signific
tabl
area
curv
best
cutoff
valu
respect
figur
china
grow
surveil
network
laboratori
capac
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
outbreak
identifi
within
week
viral
genom
sequenc
announc
effect
promot
vitro
diagnost
test
present
main
diagnost
method
detect
nucleic
acid
realtim
quantit
fluoresc
pcr
earli
stage
epidem
due
insuffici
product
nucleic
acid
detect
kit
high
requir
technic
norm
nucleic
acid
detect
applic
nucleic
acid
test
diagnost
standard
limit
bodi
immun
system
produc
antibodi
clinic
sign
symptom
obviou
viru
like
declin
without
detect
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
recent
studi
patient
show
high
proport
suspect
nosocomi
infect
also
noteworthi
presenc
asymptomat
patient
latent
mild
pneumonia
may
import
sourc
infect
outbreak
transmiss
therefor
remain
critic
appli
fast
conveni
detect
method
distinguish
trace
suspici
case
contact
earli
possibl
order
prevent
supertransmiss
event
antibodi
product
humor
immun
respons
infect
virus
new
infecti
diseas
detect
nucleic
acid
use
wide
specif
antibodi
use
determin
whether
patient
recent
infect
report
serum
sampl
patient
detect
selfmad
igg
igm
elisa
kit
antigen
could
cover
np
amino
acid
gener
speak
immun
respons
pathogen
microorgan
usual
stimul
rise
igm
infect
igg
usual
appear
week
igm
rise
maintain
high
level
bodi
long
time
new
infecti
diseas
immunolog
test
reagent
develop
still
report
igm
igg
antibodi
produc
develop
infect
studi
found
specif
antibodi
reactiv
appear
onset
morbid
patient
unlik
previou
experi
igg
usual
appear
week
igm
presenc
igm
antibodi
case
follow
presenc
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
highli
infecti
popul
gener
suscept
common
symptom
infect
includ
fever
fatigu
dri
cough
muscl
pain
expiratori
dyspnoea
occur
half
patient
sever
case
prone
rapidli
progress
acut
respiratori
distress
syndrom
septic
shock
high
risk
admiss
intens
care
unit
even
death
therefor
close
observ
condit
morbid
find
sever
case
soon
possibl
key
reduc
mortal
critic
ill
patient
accord
find
seem
time
speed
product
specif
igm
antibodi
correl
diseas
sever
number
case
small
research
need
confirm
addit
fever
patient
diseas
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
medic
staff
healthi
control
also
studi
group
includ
sever
respiratori
virus
influenza
b
adenoviru
infect
case
case
neg
specif
antibodi
detect
indic
antibodi
detect
good
abil
resist
interfer
differenti
consid
broken
mani
countri
around
world
peopl
diagnos
number
grow
rapidli
main
problem
present
need
highli
sensit
test
screen
suspect
case
prevent
miss
diagnosi
nucleic
acid
test
lower
fals
posit
rate
antibodi
test
accept
meantim
patient
morbid
week
simultan
posit
igm
igg
help
improv
specif
compar
nucleic
acid
test
requir
respiratori
tract
sampl
complex
test
procedur
oper
requir
serum
antibodi
detect
clinic
laboratori
lower
nucleic
acid
detect
detect
quickli
larg
quantiti
complet
common
biosafeti
laboratori
morbid
week
nucleic
acid
detect
conveni
serolog
dynam
monitor
carri
posit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
strongli
recommend
use
nucleic
acid
diagnosi
immedi
disadvantag
nucleic
acid
detect
exist
rel
high
fals
neg
rate
serolog
antibodi
detect
advantag
high
sensit
combin
two
good
diagnost
mean
infer
futur
epidem
situat
control
certain
extent
conveni
method
antibodi
detect
still
necessari
make
differenti
diagnosi
respiratori
pathogen
infect
must
emphas
independ
result
specif
antibodi
test
use
diagnost
criteria
especi
epidemiolog
histori
unclear
must
combin
patient
morbid
time
clinic
signsit
must
emphas
independ
result
specif
antibodi
test
use
diagnost
basi
especi
epidemiolog
histori
unclear
must
combin
patient
morbid
time
clinic
sign
knowledg
littl
report
specif
antibodi
product
process
cours
diseas
littl
report
differ
situat
antibodi
fever
popul
diseas
special
contact
popul
medic
staff
healthi
popul
studi
provid
data
regular
antibodi
product
cours
provid
understand
basic
data
specif
antibodi
differ
popul
result
studi
help
provid
evid
rapid
screen
suspect
case
serolog
test
curb
rapid
progress
epidem
global
day
manuscript
submit
china
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
consid
liaon
provinc
studi
conduct
low
epidem
area
possibl
asymptomat
infect
would
small
paper
studi
produc
process
specif
antibodi
patient
compar
evalu
diagnost
valu
antibodi
differ
popul
benefici
doctor
use
process
diagnosi
treatment
use
complement
nucleic
acid
detect
specif
antibodi
abl
draw
comprehens
rapid
accur
diagnosi
effect
distinct
covid
patient
curb
rapid
spread
global
epidem
period
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
declar
compet
interest
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
laboratori
find
patient
normal
rang
white
blood
cell
count
l
neutrophil
count
l
lymphocyt
count
l
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
tabl
antibodi
product
